🔎 Trials Near Me

Akèy › Astrositòm › Massachusetts › Boston

Etid klinik pou Astrositòm nan Boston, MA

13 etid pou Astrositòm ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Ap rekriteFaz 3
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07215910

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Ap rekriteFaz 1/2
  • Tufts Medical Center, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Targeted Pediatric High-Grade Glioma Therapy

Ap rekriteEtid obsèvasyon
  • Dana-Farber Cancer Institute, Boston
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379

Serial MRI Scans During Radiation Therapy

Ap rekrite
  • Brigham and Women Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04188535

Study of Olutasidenib and Temozolomide in HGG

Ap rekriteFaz 2
  • Susan Chi, Boston
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Ap rekriteFaz 3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Ap rekriteFaz 1/2
  • Research Site, Boston
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Ap rekriteFaz 1 bonèVolontè an sante akeyi
  • Dana-Farber Cancer Institute, Boston
Laj 1 a 21 · Tout sèks · Mizajou Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Ap rekriteFaz 2
  • Dana-Farber Cancer Institute, Boston
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253

Implantable Microdevice In Primary Brain Tumors

Ap rekriteFaz 1 bonè
  • Brigham and Women's Hospital, Boston
Laj 18 ak plis · Tout sèks · Mizajou Jul 23, 2025 · NCT04135807

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

Ap rekriteEtid obsèvasyon
  • Massachusetts General Hospital, Boston
Laj 18 a 90 · Tout sèks · Mizajou Feb 28, 2024 · NCT06283927

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Ap rekriteEtid obsèvasyon
  • Massachusetts General Hospital, Boston
Jiska laj 90 · Tout sèks · Mizajou Feb 22, 2024 · NCT06273176

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

Ap rekriteEtid obsèvasyon
  • Massachusetts General Hospital, Boston
Laj 18 a 90 · Tout sèks · Mizajou Feb 22, 2024 · NCT06118723

Etid Astrositòm nan lòt vil

Lòt etid nan Boston

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.